vs

Side-by-side financial comparison of BayCom Corp (BCML) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $25.9M, roughly 1.4× BayCom Corp). BayCom Corp runs the higher net margin — 26.5% vs -304.2%, a 330.7% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 9.4%). BayCom Corp produced more free cash flow last quarter ($30.1M vs $-47.3M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 2.9%).

BayCom Corp is a U.S.-headquartered bank holding company operating through its wholly owned subsidiary Bay Commercial Bank. It primarily serves small and medium-sized enterprises and retail customers across Northern California, offering commercial lending, deposit products, personal banking services, and localized wealth management solutions.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

BCML vs RXRX — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.4× larger
RXRX
$35.5M
$25.9M
BCML
Growing faster (revenue YoY)
RXRX
RXRX
+672.3% gap
RXRX
681.7%
9.4%
BCML
Higher net margin
BCML
BCML
330.7% more per $
BCML
26.5%
-304.2%
RXRX
More free cash flow
BCML
BCML
$77.4M more FCF
BCML
$30.1M
$-47.3M
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
2.9%
BCML

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BCML
BCML
RXRX
RXRX
Revenue
$25.9M
$35.5M
Net Profit
$6.9M
$-108.1M
Gross Margin
59.8%
Operating Margin
36.6%
-304.8%
Net Margin
26.5%
-304.2%
Revenue YoY
9.4%
681.7%
Net Profit YoY
12.1%
39.6%
EPS (diluted)
$0.63
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCML
BCML
RXRX
RXRX
Q4 25
$25.9M
$35.5M
Q3 25
$25.7M
$5.2M
Q2 25
$24.7M
$19.2M
Q1 25
$24.3M
$14.7M
Q4 24
$23.7M
$4.5M
Q3 24
$25.6M
$26.1M
Q2 24
$23.8M
$14.4M
Q1 24
$24.5M
$13.8M
Net Profit
BCML
BCML
RXRX
RXRX
Q4 25
$6.9M
$-108.1M
Q3 25
$5.0M
$-162.3M
Q2 25
$6.4M
$-171.9M
Q1 25
$5.7M
$-202.5M
Q4 24
$6.1M
$-178.9M
Q3 24
$6.0M
$-95.8M
Q2 24
$5.6M
$-97.5M
Q1 24
$5.9M
$-91.4M
Gross Margin
BCML
BCML
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
BCML
BCML
RXRX
RXRX
Q4 25
36.6%
-304.8%
Q3 25
26.3%
-3327.6%
Q2 25
35.3%
-916.8%
Q1 25
31.6%
-1297.9%
Q4 24
34.2%
-4042.4%
Q3 24
32.4%
-377.1%
Q2 24
31.9%
-697.4%
Q1 24
33.3%
-698.4%
Net Margin
BCML
BCML
RXRX
RXRX
Q4 25
26.5%
-304.2%
Q3 25
19.5%
-3135.3%
Q2 25
25.8%
-894.2%
Q1 25
23.4%
-1373.3%
Q4 24
25.9%
-3935.5%
Q3 24
23.5%
-367.5%
Q2 24
23.6%
-676.6%
Q1 24
24.0%
-662.4%
EPS (diluted)
BCML
BCML
RXRX
RXRX
Q4 25
$0.63
$-0.17
Q3 25
$0.46
$-0.36
Q2 25
$0.58
$-0.41
Q1 25
$0.51
$-0.50
Q4 24
$0.55
$-0.56
Q3 24
$0.54
$-0.34
Q2 24
$0.50
$-0.40
Q1 24
$0.51
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCML
BCML
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$338.6M
$1.1B
Total Assets
$2.6B
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCML
BCML
RXRX
RXRX
Q4 25
$743.3M
Q3 25
$659.8M
Q2 25
$525.1M
Q1 25
$500.5M
Q4 24
$594.4M
Q3 24
$427.6M
Q2 24
$474.3M
Q1 24
$296.3M
Total Debt
BCML
BCML
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
BCML
BCML
RXRX
RXRX
Q4 25
$338.6M
$1.1B
Q3 25
$334.3M
$1.0B
Q2 25
$330.6M
$919.1M
Q1 25
$329.3M
$933.9M
Q4 24
$324.4M
$1.0B
Q3 24
$321.7M
$524.6M
Q2 24
$315.3M
$584.4M
Q1 24
$314.2M
$401.2M
Total Assets
BCML
BCML
RXRX
RXRX
Q4 25
$2.6B
$1.5B
Q3 25
$2.6B
$1.4B
Q2 25
$2.6B
$1.3B
Q1 25
$2.6B
$1.3B
Q4 24
$2.7B
$1.4B
Q3 24
$2.6B
$726.5M
Q2 24
$2.6B
$775.9M
Q1 24
$2.6B
$557.8M
Debt / Equity
BCML
BCML
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCML
BCML
RXRX
RXRX
Operating Cash FlowLast quarter
$31.8M
$-46.1M
Free Cash FlowOCF − Capex
$30.1M
$-47.3M
FCF MarginFCF / Revenue
116.2%
-133.1%
Capex IntensityCapex / Revenue
6.7%
3.5%
Cash ConversionOCF / Net Profit
4.64×
TTM Free Cash FlowTrailing 4 quarters
$51.1M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCML
BCML
RXRX
RXRX
Q4 25
$31.8M
$-46.1M
Q3 25
$7.3M
$-117.4M
Q2 25
$6.4M
$-76.4M
Q1 25
$9.3M
$-132.0M
Q4 24
$30.4M
$-115.4M
Q3 24
$9.6M
$-59.2M
Q2 24
$7.7M
$-82.2M
Q1 24
$5.1M
$-102.3M
Free Cash Flow
BCML
BCML
RXRX
RXRX
Q4 25
$30.1M
$-47.3M
Q3 25
$6.2M
$-117.6M
Q2 25
$5.6M
$-79.6M
Q1 25
$9.1M
$-133.8M
Q4 24
$28.7M
$-116.7M
Q3 24
$9.4M
$-63.8M
Q2 24
$7.4M
$-83.4M
Q1 24
$3.9M
$-109.0M
FCF Margin
BCML
BCML
RXRX
RXRX
Q4 25
116.2%
-133.1%
Q3 25
24.3%
-2272.5%
Q2 25
22.8%
-413.9%
Q1 25
37.6%
-907.4%
Q4 24
121.1%
-2567.7%
Q3 24
36.6%
-244.6%
Q2 24
31.2%
-578.5%
Q1 24
16.1%
-789.9%
Capex Intensity
BCML
BCML
RXRX
RXRX
Q4 25
6.7%
3.5%
Q3 25
4.3%
4.7%
Q2 25
3.0%
16.4%
Q1 25
0.6%
12.4%
Q4 24
7.2%
28.6%
Q3 24
1.0%
17.5%
Q2 24
1.0%
8.2%
Q1 24
4.7%
48.2%
Cash Conversion
BCML
BCML
RXRX
RXRX
Q4 25
4.64×
Q3 25
1.47×
Q2 25
1.00×
Q1 25
1.63×
Q4 24
4.96×
Q3 24
1.60×
Q2 24
1.37×
Q1 24
0.86×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons